Skip to content

Ultrasound-guided Combined Perineural and Intramuscular Dextrose Injection for Management of Refractory Bell's Palsy

Ultrasound-guided Combined Perineural and Intramuscular Dextrose Injection for Management of Refractory Bell's Palsy A Prospective Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07728331
Enrollment
30
Registered
2026-07-27
Start date
2025-10-10
Completion date
2026-04-01
Last updated
2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bell Palsy

Brief summary

Bell's palsy (BP) is characterized by idiopathic acute weakness of the facial muscles associated with compression of the facial nerve. The present prospective study sought to evaluate the clinical efficacy of ultrasound-guided combined perineural and intramuscular dextrose injection for management of refractory Bell's palsy. The study included 30 patients with Bell's palsy with House-Brackmann scale ≥ 3 who were refractory to standard medical treatment after 3 months of disease onset. They received ultrasound-guided combined perineural and intramuscular dextrose injection. Clinical outcome was assessed using the House-Brackmann scale.

Interventions

PROCEDUREUltrasound-guided combined perineural and intramuscular dextrose injection.

Ultrasound-guided combined perineural and intramuscular dextrose injection.

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

\- The study included 30 patients with Bell's palsy diagnosed according to the recommendations of American Academy of Otolaryngology-Head and Neck Surgery Foundation

Exclusion criteria

* Patients were excluded if they were previously submitted to injection therapy or surgical intervention for management of Bell's palsy. They were also excluded if they had associated mental illness or advanced systemic conditions (e.g. uncontrolled diabetes, uncontrolled hypertension, malignant disease, immunocompromised conditions).

Design outcomes

Primary

MeasureTime frameDescription
House Brackmann scale3 monthsHouse Brackmann scale

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 28, 2026